<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Dermatol Ther (Heidelb)</journal-id><journal-id journal-id-type="iso-abbrev">Dermatol Ther (Heidelb)</journal-id><journal-title-group><journal-title>Dermatology and Therapy</journal-title></journal-title-group><issn pub-type="ppub">2193-8210</issn><issn pub-type="epub">2190-9172</issn><publisher><publisher-name>Springer Healthcare</publisher-name><publisher-loc>Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25616908</article-id><article-id pub-id-type="pmc">4374064</article-id><article-id pub-id-type="publisher-id">69</article-id><article-id pub-id-type="doi">10.1007/s13555-015-0069-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: Sorafenib-Associated Facial Acneiform Eruption</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Cohen</surname><given-names>Philip R.</given-names></name><address><email>mitehead@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Division of Dermatology, University of California San Diego, 10991 Twinleaf Court, Twinleaf Court, California 92131-3643 USA </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>1</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>1</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2015</year></pub-date><volume>5</volume><issue>1</issue><fpage>87</fpage><lpage>89</lpage><history><date date-type="received"><day>3</day><month>11</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2015</copyright-statement></permissions><related-article related-article-type="corrected-article" id="d30e91" ext-link-type="doi" xlink:href="10.1007/s13555-014-0067-9"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Healthcare 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Erratum to: Dermatol Ther (Heidelb) (2014) 5(1) DOI 10.1007/s13555-014-0067-9</title><p>The author of the above-mentioned paper noticed some errors subsequent to publication and would like to make the following correction.</p><p>On page&#x000a0;6 there is to be a change to the labelling of <bold>Table&#x000a0;2</bold> footnotes. &#x0201c;<bold>Table&#x000a0;2</bold> Characteristics of patients with sorafenib-associated facial acneiform facial eruptions&#x0201d; is to be replaced with the following:
<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Characteristics of patients with sorafenib-associated facial acneiform facial eruptions</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Case [Ref.]</th><th align="left">1 [37]</th><th align="left">2 [38] C1</th><th align="left">3 [39]</th><th align="left">4 [38] C2</th><th align="left">5 CR</th></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left">42</td><td align="left">51</td><td align="left">52</td><td align="left">65</td><td align="left">79</td></tr><tr><td align="left">Race</td><td align="left">NS</td><td align="left">White</td><td align="left">White</td><td align="left">White</td><td align="left">Asian</td></tr><tr><td align="left">Sex</td><td align="left">Female</td><td align="left">Male</td><td align="left">Male</td><td align="left">Male</td><td align="left">Male</td></tr><tr><td align="left">Ca</td><td align="left">LEH</td><td align="left">mRCC</td><td align="left">mRC</td><td align="left">mRCC</td><td align="left">HCC</td></tr><tr><td align="left">FAL</td><td align="left">+</td><td align="left">+<sup>b</sup>
</td><td align="left">+</td><td align="left">+<sup>d</sup>
</td><td align="left">+<sup>f</sup>
</td></tr><tr><td align="left">OSAL</td><td align="left">Trunk (upper)</td><td align="left">Arms, axillae, back (upper), chest (upper)</td><td align="left">Genital area, neck, scalp</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Symptoms</td><td align="left">&#x02013;</td><td align="left">Burning sensation, oiliness (increased), pruritus</td><td align="left">Pain</td><td align="left">Oiliness (increased)</td><td align="left">&#x02013;</td></tr><tr><td align="left">Lesion morph</td><td align="left">Papules, pustules</td><td align="left">Open comedones&#x000a0;=&#x000a0;closed comedones (Ca-L)</td><td align="left">Papules, pustules</td><td align="left">Open comedones&#x000a0;=&#x000a0;closed comedones (Ca-L)</td><td align="left">Open comedones&#x000a0;&#x0003e;&#x000a0;closed comedones (Ca-L)</td></tr><tr><td align="left">Soraf dose</td><td align="left">400&#x000a0;mg BID&#x000a0;&#x000d7;&#x000a0;4&#x000a0;weeks, then 800&#x000a0;mg BID</td><td align="left">400&#x000a0;mg BID</td><td align="left">600&#x000a0;mg QD</td><td align="left">400&#x000a0;mg BID</td><td align="left">400&#x000a0;mg BID</td></tr><tr><td align="left">Onset<sup>a</sup>
</td><td align="left">4.1</td><td align="left">6</td><td align="left">4</td><td align="left">8</td><td align="left">1.3</td></tr><tr><td align="left">OSCAE</td><td align="left">NS</td><td align="left">NS</td><td align="left">Alopecia, HFSR, SFFH, Sp-l</td><td align="left">NS</td><td align="left">Alopecia, HFSR, ISK, SD-LE, xerosis</td></tr><tr><td align="left">Treatment</td><td align="left">Cleared 2&#x000a0;weeks after Soraf dose lowered to 400&#x000a0;mg BID</td><td align="left">70% improvement after BP&#x000a0;&#x000d7;&#x000a0;2&#x000a0;months</td><td align="left">Improvement after oral tetracycline and topical: BP, EES, Flu, and Met</td><td align="left">Tret 0.05%</td><td align="left">Clin, Tret 0.025%</td></tr><tr><td align="left">Comment</td><td align="left">Pt died 2&#x000a0;months after lowering dose of Soraf from cancer prog</td><td align="left">
<sup>c</sup>
</td><td align="left">Soraf stopped for surgery; ACE reappeared when restarted soraf</td><td align="left">Exposure to Agent Orange in Vietnam<sup>e</sup>
</td><td align="left">Lesions slowly resolving with topical therapy after stop Soraf</td></tr></tbody></table><table-wrap-foot><p>
<italic>ACE</italic> acneiform eruption, <italic>BID</italic> twice daily, <italic>BP</italic> benzoyl peroxide, <italic>Ca</italic> cancer, <italic>Ca-L</italic> chloracne-like, <italic>C</italic> case, <italic>Clin</italic> clindamycin 1% solution twice daily, <italic>CR</italic> current report, <italic>EES</italic> erythromycin, <italic>FAL</italic> facial acneiform lesions, <italic>Flu</italic> fluocinonide cream, <italic>HCC</italic> hepatocellular carcinoma, <italic>HFSR</italic> hand&#x02013;foot skin reaction, <italic>ISK</italic> inflamed seborrheic keratosis, <italic>LEH</italic> liver epithelioid hemangioendothelioma, <italic>Met</italic> metronidazole, <italic>mRC</italic> metastatic renal carcinoma, <italic>mRCC</italic> metastatic renal cell carcinoma, <italic>NS</italic> not stated, <italic>OSAL</italic> other sites of acneiform lesions, <italic>OSCAE</italic> other sorafenib-associated cutaneous adverse events, <italic>prog</italic> progression, <italic>Pt</italic> patient, <italic>QD</italic> daily, <italic>SD-LE</italic> seborrheic dermatitis-like eruption, <italic>SFFH</italic> spiny filiform follicular hyperkeratosis, <italic>soraf</italic> sorafenib, <italic>Sp-l</italic> sandpaper-like skin texture, <italic>Tret 0.025%</italic> tretinoin 0.025% cream each evening, <italic>Tret 0.05%</italic> tretinoin 0.05% cream each evening, + present, &#x02212; absent</p><p>
<sup>a</sup>Number of weeks on sorafenib prior to appearance of acneiform eruption</p><p>
<sup>b</sup>The facial acneiform lesions were located on bilateral malar cheeks and postauricular areas</p><p>
<sup>c</sup>A skin biopsy of an acneiform lesion showed milia-like cyst with a sparse lymphocytic inflammatory dermal infiltrate</p><p>
<sup>d</sup>The facial acneiform lesions were located on the nose and bilateral malar cheeks, temples and postauricular areas</p><p>
<sup>e</sup>The patient did not return for follow up examination</p><p>
<sup>f</sup>The facial acneiform lesions were located on bilateral malar cheeks, preauricular areas, ears and postauricular areas</p></table-wrap-foot></table-wrap></p></sec></body><back><fn-group><fn><p>The online version of the original article can be found under doi:10.1007/s13555-014-0067-9.</p></fn></fn-group><ack><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</p></ack></back></article>